Tiziana Life Sciences (NASDAQ:TLSA) CEO Buys $667,000.00 in Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi acquired 667,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $1.00 per share, with a total value of $667,000.00. Following the completion of the acquisition, the chief executive officer owned 4,472,261 shares in the company, valued at approximately $4,472,261. The trade was a 17.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi bought 237,616 shares of Tiziana Life Sciences stock. The stock was purchased at an average price of $1.00 per share, for a total transaction of $237,616.00.
• On Tuesday, August 4th, Ivor Elrifi purchased 83,807 shares of Tiziana Life Sciences stock. The shares were purchased at an average cost of $0.97 per share, with a total value of $81,292.79.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ:TLSA opened at $1.00 on Friday. The business has a 50-day moving average of $1.13 and a two-hundred day moving average of $1.30. Tiziana Life Sciences Ltd has a 12 month low of $0.87 and a 12 month high of $2.53.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TLSA. Millennium Management LLC acquired a new stake in shares of Tiziana Life Sciences during the 3rd quarter valued at approximately $520,000. Jane Street Group LLC boosted its holdings in shares of Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock valued at $181,000 after buying an additional 151,858 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Tiziana Life Sciences by 413.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock valued at $164,000 after buying an additional 88,830 shares during the last quarter. Bison Wealth LLC acquired a new stake in Tiziana Life Sciences during the fourth quarter worth about $30,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences during the fourth quarter worth about $59,000.

Analyst Ratings Changes

Several equities research analysts have issued reports on TLSA shares. Weiss Ratings downgraded shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen cut shares of Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tiziana Life Sciences presently has an average rating of “Reduce”.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.